Yahya Ahmadipour

Dr. Yahya Ahmadipour

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in World Neurosurgery
Verified
Journal Article
Closed access
OGOliver Gembruch
Oliver Gembruch
AJAndreas Junker
Andreas Junker
CMChristoph Mönninghoff
Christoph Mönninghoff
YAYahya Ahmadipour
Yahya Ahmadipour
MOMarvin Darkwah Oppong
Marvin Darkwah Oppong
ELElias Lemonas
Elias Lemonas

1 February 2019 in World Neurosurgery
Verified
Journal Article
Closed access
YAYahya Ahmadipour
Yahya Ahmadipour
RJRamazan Jabbarli
Ramazan Jabbarli
OGOliver Gembruch
Oliver Gembruch
DPDaniela Pierscianek
Daniela Pierscianek
MOMarvin Darkwah Oppong
Marvin Darkwah Oppong
NHNicolai El Hindy
Nicolai El Hindy

1 June 2020 in Neurochirurgie
Verified
Journal Article
Closed access
YAYahya Ahmadipour
Yahya Ahmadipour
OGOliver Gembruch
Oliver Gembruch
DPD. Pierscianek
D. Pierscianek
USU. Sure
U. Sure
RJRamazan Jabbarli
Ramazan Jabbarli

1 November 2018 in World Neurosurgery
Verified
Journal Article
Closed access
MOMarvin Darkwah Oppong
Marvin Darkwah Oppong
DPDaniela Pierscianek
Daniela Pierscianek
YAYahya Ahmadipour
Yahya Ahmadipour
TDThiemo Florin Dinger
Thiemo Florin Dinger
PDPhilipp Dammann
Philipp Dammann
RJRamazan Jabbarli
Ramazan Jabbarli

9 April 2019 in Journal of Neurological Surgery Part A: Central European Neurosurgery
Verified
Journal Article
Closed access
PDF file
YAYahya Ahmadipour
Yahya Ahmadipour
MKMonika Kaur
Monika Kaur
DPDaniela Pierscianek
Daniela Pierscianek
OGOliver Gembruch
Oliver Gembruch
MOMarvin Darkwah Oppong
Marvin Darkwah Oppong
NHNicolai El Hindy
Nicolai El Hindy
Objective Extent of resection (EOR) and Karnofsky Performance Status (KPS) are at odds in glioblastoma (GBM) surgery, that is, the anticipated postoperative disability limits the EOR. This study analyzes the correlation of different surgical modalities with the resulting physical status and survival of patients with GBM. Methods A total of 565 patients with primary GBM were operated on in a single institution between 2006 and 2014. Possible surgical modalities comprised supratotal resection (SLR), gross total resection (GTR; ≥ 95% by volume), tumor debulking (TDB; ≤ 95% by volume), and stereotactic biopsy (SB). Pre- and postoperative KPS before and up to 4 weeks after surgery as well as overall survival (OS) rate were determined retrospectively. Hazard ratio (HR) and 95% confidence intervals were calculated using a Cox proportional hazards model. Results Median postoperative KPS was ≥ 70, irrespective of surgical modality. Mean OS was 12.5 months. Multivariate analysis revealed age ≥ 70 years (HR: 1.93), preoperative KPS < 70 (HR: 2.15), and unmethylation in MGMT promoter (HR: 1.27) as independent factors for worse OS. Regarding surgical modality, SB was associated with the worst survival (HR: 2.3) followed by TDB (HR: 1.36). SLR was inferior to GTR (HR: 1.27). Conclusion Higher EOR in patients with GBM does not seem inevitably correlated with increasing functional impairment, but better survival, provided there is a balanced preoperative indication. Nevertheless, SLR does not seem to be superior to GTR. Whenever possible, maximal safe resection should be considered in patients with GBM, even if an EOR ≥ 95% is not possible.

27 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
RJRamazan Jabbarli
Ramazan Jabbarli
YAYahya Ahmadipour
Yahya Ahmadipour
LRLaurèl Rauschenbach
Laurèl Rauschenbach
ASAlejandro N. Santos
Alejandro N. Santos
MOMarvin Darkwah Oppong
Marvin Darkwah Oppong
KWKarsten Henning Wrede
Karsten Henning Wrede
Despite multimodal treatment, the prognosis of patients with glioblastoma (GBM) remains poor. Previous studies showed conflicting results on the effect of antiepileptic drugs (AED) on GBM survival. We investigated the associations of different AED with overall survival (OS) and progression-free survival (PFS) in a large institutional GBM cohort (n = 872) treated January 2006 and December 2018. In addition, we performed a meta-analysis of previously published studies, including this study, to summarize the evidence on the value of AED for GBM prognosis. Of all perioperatively administered AED, only the use of levetiracetam (LEV) was associated with longer OS (median: 12.8 vs. 8.77 months, p < 0.0001) and PFS (7 vs. 4.5 months, p = 0.001). In the multivariable analysis, LEV was independently associated with longer OS (aHR = 0.74, p = 0.017) and PFS (aHR = 0.68, p = 0.008). In the meta-analysis with 5614 patients from the present and seven previously published studies, outcome benefit for OS (HR = 0.83, p = 0.02) and PFS (HR = 0.77, p = 0.02) in GBM individuals with LEV was confirmed. Perioperative treatment with LEV might improve the prognosis of GBM patients. We recommend a prospective randomized controlled trial addressing the efficacy of LEV in GBM treatment.